Search results
FDA approves higher dose of Catalyst's LEMS drug By Investing.com
Investing.com· 6 days agoCatalyst Pharmaceuticals, Inc. (NASDAQ: CPRX), a commercial-stage biopharmaceutical company,...
What Does the Year-End Election Hold for ETFs?
Zacks via Yahoo Finance· 8 hours agoIn contrast, Trump’s potential policies may include extending the 2017...Investment Perspectives Regardless of the election outcome, Berkshire Hathaway ...
Millionaire Makers: 7 Stocks You Can Buy for $2 That Can 10X by 2025
InvestorPlace· 1 hour agoThese 10X penny stocks have the potential to mint millionaires with enough capital but buy wisely as...
Vita Biotech Retains CBIH Services for Clinical Studies
Digital Journal· 7 hours agoCBIH and Vita Biotech look forward to potentially bolster the credibility of our research among leading pharmaceutical companies, paving the way as pioneers in medical cannabis ...
Viking's MASH drug scored where Madrigal's didn't, but shares fall on lack of direction
FierceBiotech· 1 day agoViking Therapeutics is pulling up some extra long boats full of reasons the metabolic...
Health Care Roundup: Market Talk
The Wall Street Journal· 6 days ago(alice.uribe@wsj.com) 1717 ET – Padraig McDonnell steps into a tough spot just a few weeks after becoming CEO at Agilent. The laboratory-supplies company...
Earnings call: UiPath outlines growth amidst challenges, revises outlook By Investing.com
Investing.com· 6 days agoDespite these positive figures, UiPath's CEO Daniel Dines acknowledged that the company's...
Earnings call: Roivant reveals Q4 2023 results and strategic growth plans By Investing.com
Investing.com· 6 days agoCEO Matt Gline provided insights into the company's strategic plans for growth, emphasizing the...
